Vardenafil Hydrochloride Patent Expiration

Vardenafil Hydrochloride is Used for treating erectile dysfunction. It was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Levitra on Aug 19, 2003. Another drug containing Vardenafil Hydrochloride is Staxyn. 8 different companies have introduced drugs containing Vardenafil Hydrochloride.


Vardenafil Hydrochloride Patents

Given below is the list of patents protecting Vardenafil Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Staxyn US8613950 Pharmaceutical forms with improved pharmacokinetic properties Dec 23, 2028 Bayer Hlthcare
Levitra US8273876 Medicaments containing vardenafil hydrochloride trihydrate Jul 23, 2027 Bayer Hlthcare
Levitra US8841446 Medicaments containing vardenafil hydrochloride trihydrate Jul 03, 2023

(Expired)

Bayer Hlthcare
Levitra US6362178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors Oct 31, 2018

(Expired)

Bayer Hlthcare
Levitra US7696206 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors Oct 31, 2018

(Expired)

Bayer Hlthcare
Staxyn US6362178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors Oct 31, 2018

(Expired)

Bayer Hlthcare
Staxyn US7696206 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors Oct 31, 2018

(Expired)

Bayer Hlthcare



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vardenafil Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Vardenafil Hydrochloride.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 09 Jun, 2021 US8613950(Litigated)
Mail O.P. Petition Decision 16 Jan, 2015 US8613950(Litigated)
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue 13 Jan, 2015 US8613950(Litigated)
O.P. Petition Decision 12 Jan, 2015 US8613950(Litigated)
Record a Petition Decision of Granted for Patent Term Adjustment after Issue 12 Jan, 2015 US8613950(Litigated)
Adjustment of PTA Calculation by PTO 07 Jan, 2015 US8613950(Litigated)
Petition Entered 21 Feb, 2014 US8613950(Litigated)
Recordation of Patent Grant Mailed 24 Dec, 2013 US8613950(Litigated)
Patent Issue Date Used in PTA Calculation 24 Dec, 2013 US8613950(Litigated)
Email Notification 05 Dec, 2013 US8613950(Litigated)


Vardenafil Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Vardenafil Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Vardenafil Hydrochloride. The first generic version for Vardenafil Hydrochloride was by Teva Pharmaceuticals Usa and was approved on May 3, 2012. And the latest generic version is by Alembic Pharmaceuticals Ltd and was approved on Aug 4, 2020.

Given below is the list of companies who have filed for Vardenafil Hydrochloride generic, along with the locations of their manufacturing plants worldwide.